Klatskin Tumor: A Survival Analysis According to Tumor Characteristics and Inflammatory Ratios.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
05 Dec 2022
Historique:
received: 17 10 2022
revised: 30 11 2022
accepted: 01 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

Background and Objectives: The aim was to evaluate the association of inflammatory biomarkers with resectability and overall survival in hilar cholangiocarcinoma. Materials and Methods: We conducted a retrospective cohort study over 72 consecutive surgical cases of Klatskin tumor over an 11-year period. The sample was divided into two groups: 42 surgical resection cases and 30 unresectable tumors. Values of inflammatory ratios were compared according to the resectability. Log-rank test, univariate, and multivariate Cox proportional hazards models were used to evaluate the overall survival. Results: Subjects were between 42−87 years old (average age of 64.91 ± 9.15 years). According to the procedure: 58.33% benefited from resection (with a 30.95% R0 resection rate) and 41.66% had palliative surgery. Elevated NLR (neutrophil to lymphocyte ratio), PLR (platelet to lymphocyte ratio), and SII (systemic immune-inflammation index), and lower LMR (lymphocyte to monocyte ratio) at admission were associated with unresectable tumors (p < 0.01). For the multivariate Cox proportional hazard models, increased absolute values of NLR, PLR, and SII were associated with lower survival; no differences were observed for LMR absolute value. The cut-off value of NLR ≥ 6 was associated with lower survival. The median survival time for all subjects was 442 days, with 774 days for the resection group and 147 days for the group with palliative surgery. Conclusions: In hilar cholangiocarcinoma, inflammatory ratios are associated with tumor resectability. Tumor excision conferred an important advantage in survival. Elevated NLR, PLR, and SII values at admission significantly increased the hazard ratio. LMR had no influence on survival.

Identifiants

pubmed: 36556990
pii: medicina58121788
doi: 10.3390/medicina58121788
pmc: PMC9785938
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Iuliu Hațieganu University of Medicine and Pharmacy
ID : PCD 1529/50/18.01.2019

Références

Ann Gastroenterol. 2018 Mar-Apr;31(2):231-236
pubmed: 29507471
J Cancer. 2019 Jan 1;10(2):494-503
pubmed: 30719145
Thorac Cancer. 2018 Jan;9(1):112-119
pubmed: 29105365
Biomed Res Int. 2018 Nov 14;2018:7375169
pubmed: 30539019
Korean J Radiol. 2018 Jul-Aug;19(4):597-605
pubmed: 29962866
Cancer Manag Res. 2019 Jun 04;11:5157-5162
pubmed: 31239770
Cancer Res Treat. 2018 Oct;50(4):1106-1113
pubmed: 29141394
Ann Surg Oncol. 2015 Dec;22(13):4363-70
pubmed: 25805235
Z Gastroenterol. 2011 Apr;49(4):436-42
pubmed: 21476179
Ann Ital Chir. 2021;92:162-171
pubmed: 34031286
World J Surg. 2012 Sep;36(9):2179-86
pubmed: 22569746
Chirurg. 2014 Feb;85(2):155-65; quiz 166-7
pubmed: 24464335
Angiogenesis. 2003;6(4):283-7
pubmed: 15166496
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S603-13
pubmed: 25900206
World J Surg. 2008 Aug;32(8):1757-62
pubmed: 18340479
Am Surg. 2012 Apr;78(4):471-7
pubmed: 22472407
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
pubmed: 11573044
World J Surg. 2016 Oct;40(10):2451-9
pubmed: 27206402
Chirurg. 1997 Apr;68(4):378-84
pubmed: 9206632
Clin Liver Dis. 2008 Feb;12(1):131-50, ix
pubmed: 18242501
Clin Colorectal Cancer. 2017 Dec;16(4):264-274
pubmed: 28412137
Sci Rep. 2016 Oct 03;6:33789
pubmed: 27694951
J Hepatobiliary Pancreat Sci. 2016 Oct;23(10):636-642
pubmed: 27474781
In Vivo. 2007 Mar-Apr;21(2):147-61
pubmed: 17436563
Anticancer Res. 2017 Jun;37(6):3229-3237
pubmed: 28551669
J Thorac Cardiovasc Surg. 2009 Feb;137(2):425-8
pubmed: 19185164
J Immunol Methods. 1999 Dec 17;232(1-2):121-9
pubmed: 10618514
Ann Surg. 2003 Jul;238(1):73-83
pubmed: 12832968
Comb Chem High Throughput Screen. 2021;24(9):1428-1435
pubmed: 33081678
World J Gastroenterol. 2007 Mar 7;13(9):1422-6
pubmed: 17457974
J Clin Med. 2020 Sep 29;9(10):
pubmed: 33003424
J Gastrointest Surg. 2019 Mar;23(3):510-517
pubmed: 30076591
Sci Rep. 2018 Feb 7;8(1):2535
pubmed: 29416061
Liver Int. 2011 Jan;31(1):99-107
pubmed: 20846273
Oncotarget. 2017 May 30;8(22):36857-36868
pubmed: 28415734
Med Sci Monit. 2019 Jun 17;25:4503-4512
pubmed: 31204730
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
J Gastrointestin Liver Dis. 2007 Dec;16(4):383-9
pubmed: 18193119
J Surg Oncol. 2005 Sep 1;91(3):181-4
pubmed: 16118772

Auteurs

Vlad-Ionuţ Nechita (VI)

Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, Louis Pasteur Street, No. 6, 400349 Cluj-Napoca, Romania.
3rd Department of Surgery, "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.

Emil Moiş (E)

3rd Department of Surgery, "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.
3rd Department of Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.

Luminiţa Furcea (L)

3rd Department of Surgery, "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.
3rd Department of Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.

Mihaela-Ancuţa Nechita (MA)

"Ion Chiricuță" Oncology Institute, Republicii Street, No. 34-36, 400015 Cluj-Napoca, Romania.

Florin Graur (F)

3rd Department of Surgery, "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.
3rd Department of Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH